VCID: 14395921
Profile
Corporate information
Official name
Roche Holding AG
Registration country
Affiliated entities
Affiliated entities
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty- four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
Investments
Selected investments
| Company | Country | Date | Notes | ||
|---|---|---|---|---|---|
|
InterMune Inc Biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. |
United States | 24 Aug 2014 | Acquisition USD 8,300,000,000 (USD 8,300,000,000) deal size. Initial investment. Led the investment round. Active |
|
|
Santaris Pharma A/S |
Denmark | 4 Aug 2014 | Acquisition USD 450,000,000 (USD 450,000,000) deal size. Initial investment. Led the investment round. Active |
